Vitiligo is personal. When it comes to your skin, the best decision is your own. Wherever you are on your journey with vitiligo, we want to meet you where you are. By taking part in the Tranquillo clinical trial (or study), you could help advance research for people who have vitiligo. So, thank you for taking the time to learn more.
If you're considering treatment options, we invite you to learn more about the Tranquillo clinical trial
This study will help us learn if an oral investigational or study medicine is safe and if it could potentially treat vitiligo.
Who may participate
When you participate in a study, you’re helping to represent yourself and other people with vitiligo across the globe. Your participation could help contribute to what we know about potential treatments. So, thank you for taking the time to learn more.
It’s important to remember that this is your journey and choice. You are free to stop being in this study at any time for any reason.
Condition
Nonsegmental vitiligo
Age
18+ years
Sex
Male or Female
Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.
Additional eligibility criteria
- Have had nonsegmental vitiligo for at least three months
- Have either active or stable vitiligo
- Have vitiligo spots on your face and body
- Do not have other skin-related conditions
What to expect
Before joining the trial, you will receive an Informed Consent Document (ICD) that you will go over with the study team. This is an important part of the clinical trial process that helps you better understand what it means to take part and what you can expect to happen during the study.
If you choose to sign the ICD, you will go through a screening period to make sure this study is right for you. This screening period may last up to 30 days and at this time the doctor will know if you can continue in the study. If you continue, the treatment period will be about one year long. During this time, you will be randomly assigned to receive daily oral capsules of either the study medicine or a placebo for about one year. You have a 33% (1 in 3) chance of receiving the placebo. A placebo does not contain any active ingredients, but the study medicine and the placebo look alike.
Length of study treatment
Approximately one year
Number of study visits
Approximately 11
Follow-up
Four weeks
Withdrawal extension study
Approximately one year
An important contribution
An important contribution
Frequently asked questions
What is vitiligo?
For people with vitiligo, the relationship they have with their skin is a personal one. Because everyone’s journey with vitiligo is different, the best decision when it comes to their condition is their own.
As you may know, nonsegmental vitiligo is defined as an autoimmune condition. This means the immune system attacks healthy cells; in this case, pigment (or color)-producing cells called melanocytes.
What is the investigational (or study) medicine and how does it work?
The investigational medicine, ritlecitinib, is [a janus kinase 3 (JAK3) inhibitor. It’s thought to work by blocking the signals and cells in the body that are believed to cause vitiligo.
Will I receive the study drug?
Your study group will be chosen randomly (like flipping a coin) rather than by choice. This is called randomization, and it’s one way to help avoid bias in a research study. You have a 33% (1 in 3) chance of receiving the placebo. Since this study is double-blinded, neither you, your study doctor, nor the study team will know if you receive the study medicine or the placebo.
How is the study drug taken?
The study medicine is a once-daily oral capsule that you’ll take for approximately one year. If possible, take it around the same time every day, with or without food. On study visit days, we ask that you take your dose at the site instead of at home.
